The Next-Generation Path to Market for Emerging Biotech

The road to biopharmaceutical commercialization can be paved by the right commercial partner.

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk.

This article dissects considerations for how to reduce risk, manage costs and optimize performance while maintaining control of your asset.